DMRA logo

DAMORA THERAPEUTICS INC

DMRANASDAQ
🏆 #2306 by market capUS Equity
$839.28▲ $65.88 (+7.85%)
Simulated price
🔔
Track DMRA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.8%
7d▲ 3648.5%
14d▲ 3294.5%
30d▲ 2790.1%
ytd▲ 3651.8%
1y▲ 21093.9%
🏦Market Cap
$1.28B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
44
Weak

Trading Snapshot

Day Range
$834.11 – $843.65
52-Week Range
$16.50 – $34.89
Volume
$2.42B
Avg Volume
$2.26B
Shares Outstanding
61.5M
Next Earnings
Nov 18, 2026

Fundamentals Snapshot

Annual Revenue
$413M
Last Q Revenue
$114M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-139.34
Dividend Yield
—
Dilution (1yr)
+28.5%

Why Investors Own DMRA

  • ✓High-growth profile — revenue up -9.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

DMRA logo

DAMORA THERAPEUTICS INC

DMRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$211M▲ +1148.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▼ −63.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.7M▲ +28.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$258M▲ +$245M YoY
StockOtter · stockotter.space

About DAMORA THERAPEUTICS INC

Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$1,111.91
▲ +32.5% Upside
High Target$1,274.01
Low Target$1,037.89
Based on 17 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

DAMORA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift DMRA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

DAMORA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.